Takeda's QDENGA Receives DCGI Approval as India's First Dengue Vaccine
Takeda Biopharmaceuticals India has received approval from the Drug Controller General of India (DCGI) for QDENGA, the country's first dengue vaccine. Approved for individuals aged 4 to 60, QDENGA protects against all four dengue virus serotypes without requiring prior infection testing. The vaccine, administered in two doses, has been authorized in 43 countries and shown sustained efficacy in global trials, including Indian participants. It is expected to be available in India by mid-2027, initially through private healthcare, supporting efforts to address the growing dengue burden.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (71/100). Lens Score 49/100.
Outlets measured: businessstandard, moneycontrol, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (70–74/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 20 Jul, 06:00 am. Other outlets followed.